Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5237918 | 0.90 | ABCC2 (0.31) | ABCC2 | |
| SCHEMBL29597347 | 0.88 | ABCC2 (0.31) | ABCC2 | |
| SCHEMBL304850 | 0.88 | ABCC2 (0.31) | ABCC2 | |
| SCHEMBL5229189 | 0.87 | ABCC2 (0.31) | ABCC2 | |
| SCHEMBL5232701 | 0.86 | ABCC2 (0.32) | ABCC2 | |
| SCHEMBL5229427 | 0.86 | ABCC2 (0.33) | ABCC2 | |
| SCHEMBL5231831 | 0.84 | CACNA1C (0.31) | CACNA1C | |
| SCHEMBL5240179 | 0.83 | CACNA1C (0.32) | CACNA1CABCC2 | |
| SCHEMBL8226967 | 0.83 | ESR1 (0.32) | CACNA1C | |
| SCHEMBL13501610 | 0.83 | ESR1 (0.32) | CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1336612-B1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA (JP) | 2007-01-17 | — | — | EP | disclosed |
| US-6908913-B2 | Carbapenem derivatives | MEIJI SEIKI KAISHA, LTD. (JP) | 2005-06-21 | — | — | US | disclosed |
| US-20040038967-A1 | Novel carbapenem derivatives | MEIJI SEIKI KAISHA, LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1336612-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2003-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038967-A1 | Novel carbapenem derivatives | DHPS, HAMP, MCRS1 | CACNA1C 2753/4885ABCC2 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.